Details of the Drug

General Information of Drug (ID: DM51TYR)

• Drug Name: Esmolol
• Synonyms: ASL 8052-001; Brevibloc (TN); Esmolol (INN); Esmolol [INN:BAN]; Methyl p-[2-hydroxy-3-(isopropylamino)propoxy]hydrocinnamate; Methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate; Methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate; Methyl 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate; Methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate; Methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate; Benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester; (+-)-Esmolol; (+-)-methyl p-(2-hydroxy-3-(isopropylamino)propoxy)hydrocinnamate

Indication

Disease Entry	ICD 11	Status	REF
Acute supraventricular tachycardia	BC81	Approved	[1], [2]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 295.37
  Topological Polar Surface Area (xlogp); 1.9
  Rotatable Bond Count (rotbonds); 10
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The clearance of drug is 20 L/h/kg in Men [4]
  Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 3.7 hours [5]
  Metabolism: The drug is metabolized via the esterases [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.67709 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.59% [5]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [5]
  Water Solubility: The ability of drug to dissolve in water is measured as 20 mg/mL [3]
• Chemical Identifiers:
  Formula: C16H25NO4
  IUPAC Name: methyl 3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate
  Canonical SMILES: CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O
  InChI: InChI=1S/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3
  InChIKey: AQNDDEOPVVGCPG-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 59768
  ChEBI ID: CHEBI:88206
  CAS Number: 81147-92-4
  DrugBank ID: DB00187
  TTD ID: D03XTC
  VARIDT ID: DR00853
  INTEDE ID: DR0626

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[9]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Esmolol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bepridil	DM0RKS4	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Bepridil.	Angina pectoris [BA40]	[28]
Dronedarone	DMA8FS5	Moderate	Increased risk of atrioventricular block by the combination of Esmolol and Dronedarone.	Angina pectoris [BA40]	[29]
Nifedipine	DMSVOZT	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Nifedipine.	Angina pectoris [BA40]	[28]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Esmolol and Promazine.	Appearance/behaviour symptom [MB23]	[30]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Esmolol and Cariprazine.	Bipolar disorder [6A60]	[30]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Atracurium.	Corneal disease [9A76-9A78]	[31]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Mivacurium.	Corneal disease [9A76-9A78]	[31]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Pancuronium.	Corneal disease [9A76-9A78]	[31]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Tubocurarine.	Corneal disease [9A76-9A78]	[31]
Nimodipine	DMQ0RKZ	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Nimodipine.	Coronary vasospastic disease [BA85]	[28]
Pasireotide	DMHM7JS	Moderate	Increased risk of bradycardia by the combination of Esmolol and Pasireotide.	Cushing syndrome [5A70]	[32]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Esmolol and OPC-34712.	Depression [6A70-6A7Z]	[30]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hyperglycemia by the combination of Esmolol and Ethacrynic acid.	Essential hypertension [BA00]	[33]
Nicardipine	DMCDYW7	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Nicardipine.	Essential hypertension [BA00]	[28]
Phenylephrine	DMZHUO5	Moderate	Additive hypertensive effects by the combination of Esmolol and Phenylephrine.	Faecal incontinence [ME07]	[34]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Esmolol caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[35]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Esmolol and Prazosin.	Heart failure [BD10-BD1Z]	[36]
Chlorothiazide	DMLHESP	Moderate	Increased risk of hyperglycemia by the combination of Esmolol and Chlorothiazide.	Heart failure [BD10-BD1Z]	[33]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Esmolol and Furosemide.	Heart failure [BD10-BD1Z]	[33]
Bumetanide	DMRV7H0	Moderate	Increased risk of hyperglycemia by the combination of Esmolol and Bumetanide.	Heart failure [BD10-BD1Z]	[33]
Torasemide	DMXKJ6C	Moderate	Increased risk of hyperglycemia by the combination of Esmolol and Torasemide.	Heart failure [BD10-BD1Z]	[33]
Nisoldipine	DM7ISKJ	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Nisoldipine.	Hypertension [BA00-BA04]	[28]
Levamlodipine	DM92S6N	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Levamlodipine.	Hypertension [BA00-BA04]	[28]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Esmolol and Doxazosin.	Hypertension [BA00-BA04]	[36]
Isradipine	DMA5XGH	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Isradipine.	Hypertension [BA00-BA04]	[28]
Verapamil	DMA7PEW	Major	Increased risk of cardiac depression by the combination of Esmolol and Verapamil.	Hypertension [BA00-BA04]	[28]
Diltiazem	DMAI7ZV	Major	Increased risk of cardiac depression by the combination of Esmolol and Diltiazem.	Hypertension [BA00-BA04]	[28]
Amlodipine	DMBDAZV	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Amlodipine.	Hypertension [BA00-BA04]	[28]
Indapamide	DMGN1PW	Moderate	Increased risk of hypertriglyceridemia by the combination of Esmolol and Indapamide.	Hypertension [BA00-BA04]	[33]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of hyperglycemia by the combination of Esmolol and Trichlormethiazide.	Hypertension [BA00-BA04]	[33]
Felodipine	DMOSW35	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Felodipine.	Hypertension [BA00-BA04]	[28]
Clevidipine butyrate	DMW4M97	Moderate	Increased risk of cardiac depression by the combination of Esmolol and Clevidipine butyrate.	Hypertension [BA00-BA04]	[28]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Esmolol and Propiomazine.	Insomnia [7A00-7A0Z]	[30]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Esmolol and ITI-007.	Insomnia [7A00-7A0Z]	[30]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Esmolol and Thalidomide.	Multiple myeloma [2A83]	[37]
Siponimod	DM2R86O	Major	Increased risk of bradycardia by the combination of Esmolol and Siponimod.	Multiple sclerosis [8A40]	[37]
Fingolimod	DM5JVAN	Major	Increased risk of bradycardia by the combination of Esmolol and Fingolimod.	Multiple sclerosis [8A40]	[38]
Ozanimod	DMT6AM2	Moderate	Increased risk of atrioventricular block by the combination of Esmolol and Ozanimod.	Multiple sclerosis [8A40]	[39]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Esmolol and Prochlorperazine.	Nausea/vomiting [MD90]	[30]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Esmolol and Promethazine.	Nausea/vomiting [MD90]	[30]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Esmolol and Thiethylperazine.	Nausea/vomiting [MD90]	[30]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Esmolol and Terazosin.	Prostate hyperplasia [GA90]	[36]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Esmolol and Silodosin.	Prostate hyperplasia [GA90]	[36]
Alfuzosin	DMZVMKF	Moderate	Additive hypotensive effects by the combination of Esmolol and Alfuzosin.	Prostate hyperplasia [GA90]	[36]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Esmolol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[30]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Esmolol and Fluphenazine.	Psychotic disorder [6A20-6A25]	[30]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Esmolol and Triflupromazine.	Psychotic disorder [6A20-6A25]	[30]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Esmolol and Quetiapine.	Schizophrenia [6A20]	[30]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Esmolol and Mesoridazine.	Schizophrenia [6A20]	[30]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Esmolol and Thioridazine.	Schizophrenia [6A20]	[30]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Esmolol and Aripiprazole.	Schizophrenia [6A20]	[30]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Esmolol and Iloperidone.	Schizophrenia [6A20]	[30]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Esmolol and Paliperidone.	Schizophrenia [6A20]	[30]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Esmolol and Loxapine.	Schizophrenia [6A20]	[30]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Esmolol and Haloperidol.	Schizophrenia [6A20]	[30]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Esmolol and Perphenazine.	Schizophrenia [6A20]	[30]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Esmolol and Molindone.	Schizophrenia [6A20]	[30]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Esmolol and Chlorpromazine.	Schizophrenia [6A20]	[30]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Esmolol and Thiothixene.	Schizophrenia [6A20]	[30]
Clozapine	DMFC71L	Moderate	Additive hypotensive effects by the combination of Esmolol and Clozapine.	Schizophrenia [6A20]	[30]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Esmolol and Trifluoperazine.	Schizophrenia [6A20]	[30]
Ziprasidone	DMM58JY	Moderate	Additive hypotensive effects by the combination of Esmolol and Ziprasidone.	Schizophrenia [6A20]	[30]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Esmolol and Risperidone.	Schizophrenia [6A20]	[30]
Olanzapine	DMPFN6Y	Moderate	Additive hypotensive effects by the combination of Esmolol and Olanzapine.	Schizophrenia [6A20]	[30]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Esmolol and Amisulpride.	Schizophrenia [6A20]	[40]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Esmolol and Asenapine.	Schizophrenia [6A20]	[30]
Succinylcholine	DM2ET1M	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Succinylcholine.	Tonus and reflex abnormality [MB47]	[31]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Pipecuronium.	Tonus and reflex abnormality [MB47]	[31]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Doxacurium.	Tonus and reflex abnormality [MB47]	[31]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Vecuronium.	Tonus and reflex abnormality [MB47]	[31]
Cisatracurium	DMUZPJ5	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Cisatracurium.	Tonus and reflex abnormality [MB47]	[31]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Esmolol and Rocuronium.	Tonus and reflex abnormality [MB47]	[31]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Esmolol and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[30]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Esmolol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[41]
Disopyramide	DM5SYZP	Major	Additive hypotensive effects by the combination of Esmolol and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[42]
Amiodarone	DMUTEX3	Moderate	Increased risk of atrioventricular block by the combination of Esmolol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[43]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7178).
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] BDDCS applied to over 900 drugs
• [4] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009 Jan-Feb;38(1):48-55.
• [9] Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
• [10] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [11] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [12] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [13] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [14] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [15] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [16] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [17] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [18] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [19] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [20] Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
• [21] Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
• [22] Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
• [23] Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
• [24] Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
• [25] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [26] beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
• [27] beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
• [28] Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
• [29] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [30] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [31] Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
• [32] Canadian Pharmacists Association.
• [33] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
• [34] Cass E, Kadar D, Stein HA "Hazards of phenylephrine topical medication in persons taking propranolol." Can Med Assoc J 120 (1979): 1261-2. [PMID: 221086]
• [35] Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231]
• [36] Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
• [37] Cerner Multum, Inc. "Australian Product Information.".
• [38] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [39] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [40] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [41] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [42] Bonde J, Bodtker S, Angelo HR, Svedsen TL, Kampmann JP "Atenolol inhibits the elimination of disopyramide." Eur J Clin Pharmacol 28 (1985): 41-3. [PMID: 3987784]
• [43] Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]